The Ecuadorean government is being forced to use money that could go toward relief efforts to instead pay off a multinational oil company.
Signing the TPP has provoked a debate on whether, when it comes into force, there will be a potential spike in medicines prices.
Private arbitral tribunals will be able to impose multi-million fines on States whose parliaments have dared to legislate without taking into account corporate expectations.
The liberalization of health care under the ASEAN Economic Community is clearly biased toward curative services as being more profitable than health promotion.
India has given private assurances that it will not grant licences allowing local firms to override patents and make cheap copies of drugs by big Western drugmakers.
"The battle to prevent this trade agreement from being implemented is far from over", asserts the humanitarian organization, joining the rejection that the treaty Chile signed in New Zealand arouses.
Business secretary refuses to disclose advice that could show how private health firms might sue government under US-Europe trade deal.
The inclusion of an ISDS in an EU agreement could raise the likelihood of such cases being brought against all kinds of public interest and health protecting policies in the future.
I only wish to caution that we should be wary of anyone who suggests that the decision demonstrates that ISDS isn’t problematic.
Philip Morris is dragging countries with tight tobacco regulations into costly legal battles.
A massive trade pact between 12 Pacific rim countries could limit the availability of affordable medicines, the head of the World Health Organization said
Now that the whole text of the TPPA has been released, it appears the TPPA provides many avenues for the tobacco industry to thwart and frustrate government efforts to enact stronger measures.
The vacuous “tobacco control” provision in the Trans Pacific Partnership (TPP) virtually capitulates to the demands of multinational tobacco corporations, jeopardizing nations’ health and economic welfare.
There is a paucity of information on drug prices, revenues and other relative information on the economics of the pharmaceutical market.
Les conséquences des dispositions relatives à la propriété intellectuelle contenues dans l’accord signé entre l’Union Européenne et la Tunisie et leurs conséquences sur la santé publique en Tunisie inquiètent.
Writing pharmaceutical regulations into international trade deals can have costly consequences.
Ahead of a meeting between Indian Prime Minister Modi and German Chancellor Merkel this week, European manufacturers had already protested India’s patents policy, arguing that it doesn’t protect sensitive technology.
EU trade deals with Canada and the US could endanger citizens’ rights to basic services like water and health, as negotiators are doing the work of some of the EU’s most powerful corporate lobby groups in pushing an aggressive market opening agenda in the public sector.
The TPP’s intellectual property chapter represents nothing less than a disaster for global health. Many harmful provisions still remain in the final chapter, bearing out the concerns of public health advocates.
The TPP could give pharmaceutical corporations more power to control medicine markets and “impose higher prices for longer.”